BridgeBio Pharma Net Acquisitions/Divestitures 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly net acquisitions/divestitures history and growth rate from 2018 to 2024. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- BridgeBio Pharma net acquisitions/divestitures for the quarter ending December 31, 2024 were $0M, a 0% increase year-over-year.
- BridgeBio Pharma net acquisitions/divestitures for the twelve months ending December 31, 2024 were $0M, a 0% increase year-over-year.
- BridgeBio Pharma annual net acquisitions/divestitures for 2024 were $0B, a 0% decline from 2023.
- BridgeBio Pharma annual net acquisitions/divestitures for 2023 were $0B, a 0% decline from 2022.
- BridgeBio Pharma annual net acquisitions/divestitures for 2022 were $0B, a 0% decline from 2021.
BridgeBio Pharma Annual Net Acquisitions/Divestitures
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.894B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
